{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:10:31Z","timestamp":1771614631028,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1053\/j.semnuclmed.2022.04.008","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T17:09:36Z","timestamp":1653412176000},"page":"816-823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Role for PET\/CT in Response Assessment of Malignant Pleural Mesothelioma"],"prefix":"10.1053","volume":"52","author":[{"given":"Patrick","family":"Sandach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-7701","authenticated-orcid":false,"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3581-5264","authenticated-orcid":false,"given":"Hubertus","family":"Hautzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Pl\u00f6nes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-9010","authenticated-orcid":false,"given":"Martin","family":"Metzenmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0001","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0002","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002680020021","article-title":"Treatment of malignant mesothelioma","volume":"25","author":"Jaklitsch","year":"2001","journal-title":"World J Surg"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0003","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0003-4878(00)00045-4","article-title":"The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure","volume":"44","author":"Hodgson","year":"2000","journal-title":"Ann Occup Hyg"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2486\/indhealth.45.379","article-title":"Malignant mesothelioma: global incidence and relationship with asbestos","volume":"45","author":"Bianchi","year":"2007","journal-title":"Ind Health"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0006","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(04)17102-X","article-title":"Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids","volume":"364","author":"Lopez-Rios","year":"2004","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0007","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc947","article-title":"SV40 and human tumours: myth, association or causality?","volume":"2","author":"Gazdar","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0008","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/sj.onc.1201375","article-title":"Simian virus 40, poliovaccines and human tumors: A review of recent developments","volume":"15","author":"Carbone","year":"1997","journal-title":"Oncogene"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0009","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/MCP.0b013e3283018220","article-title":"The relationship between simian virus 40 and mesothelioma","volume":"14","author":"Rivera","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","article-title":"Malignant pleural mesothelioma: A comprehensive review","volume":"13","author":"Ismail-Khan","year":"2006","journal-title":"Cancer Control"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0011","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ajco.12043","article-title":"Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review","volume":"9","author":"Linton","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0012","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3389\/fonc.2020.01742","article-title":"The use of immunohistochemistry, fluorescence in situ hybridization, and emerging epigenetic markers in the diagnosis of Malignant Pleural Mesothelioma (MPM): A review","volume":"10","author":"Rozitis","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0014","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0015","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0016","doi-asserted-by":"crossref","first-page":"S2565","DOI":"10.21037\/jtd.2018.07.65","article-title":"Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma","volume":"10","author":"Cramer","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0017","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jtho.2019.03.030","volume":"14","author":"Gomez","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103278","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: A systematic review and meta-analysis of randomized trials","volume":"160","author":"Lee","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0019","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: An open-label, multicenter, phase iii randomized trial","volume":"37","author":"Bayman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0021","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0022","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0023","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0025","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.21037\/tlcr.2020.01.16","article-title":"Chemotherapy options versus \u201cnovel\u201d therapies: How should we treat patients with malignant pleural mesothelioma","volume":"9","author":"Disselhorst","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0026","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0027","first-page":"5393","article-title":"Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM)","volume":"32","author":"Pasello","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0028","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase III trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0029","doi-asserted-by":"crossref","first-page":"e3351","DOI":"10.1097\/MD.0000000000003351","article-title":"Pemetrexed maintenance therapy following bevacizumab-containing first-line chemotherapy in advanced malignant pleural mesothelioma: A case report and literatures review","volume":"95","author":"Jing","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cllc.2020.06.025","article-title":"Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901","volume":"21","author":"Dudek","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0031","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/0284186X.2012.725944","article-title":"Opioids in pain management of mesothelioma and lung cancer patients","volume":"52","author":"Salminen","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0032","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0033","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0034","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0035","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0036","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","article-title":"iRECIST: How to do it","volume":"20","author":"Persigehl","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0037","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): Refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0038","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/0959-8049(95)00421-1","article-title":"Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group","volume":"31A","author":"Price","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0039","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2022.04.008_bib0040","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0041","doi-asserted-by":"crossref","first-page":"58105","DOI":"10.18632\/oncotarget.11171","article-title":"Comparison of the EORTC criteria and PERCIST in solid tumors: A pooled analysis and review","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0042","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MNM.0000000000001223","volume":"41","author":"Kitajima","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0043","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","article-title":"Specimen weight and volume: Important predictors of survival in malignant pleural mesothelioma","volume":"49","author":"Kircheva","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0044","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40644-021-00415-5","article-title":"Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma","volume":"21","author":"Lauk","year":"2021","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","article-title":"Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma","volume":"115","author":"Pass","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0046","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/JTO.0b013e3181dd0ef1","article-title":"Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans","volume":"5","author":"Liu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0047","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00330-008-0918-9","article-title":"Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT","volume":"18","author":"Plathow","year":"2008","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0048","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study","volume":"11","author":"Gill","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0049","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma","volume":"42","author":"Lopci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0051","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0052","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2967\/jnumed.120.245803","article-title":"Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma","volume":"62","author":"Ferdinandus","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0053","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0054","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0055","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2589-7500(21)00104-7","article-title":"The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study","volume":"3","author":"Zauderer","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0056","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-020-00669-3","article-title":"FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients","volume":"10","author":"Pavic","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0057","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1148\/radiol.2019191114","article-title":"(18)F-FDG PET\/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks","volume":"294","author":"Sibille","year":"2020","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0058","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s00259-021-05270-x","article-title":"Just another \"Clever Hans\"? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer","volume":"48","author":"Weber","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0059","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/RLU.0000000000003858","article-title":"68Ga-FAPI-04 PET\/CT Versus 18F-FDG PET\/CT in malignant peritoneal mesothelioma","volume":"47","author":"Gundogan","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0060","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.211424","article-title":"Comparison of (68)Ga-FAPI and (18)F-FDG PET\/CT in the evaluation of advanced lung cancer","author":"Wang","year":"2022","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0061","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00259-021-05266-7","article-title":"Equivalent tumor detection for early and late FAPI-46 PET acquisition","volume":"48","author":"Ferdinandus","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0062","article-title":"Pitfalls and common findings in (68)Ga-FAPI-PET - A pictorial analysis","author":"Kessler","year":"2021","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2022.04.008_bib0063","first-page":"727","article-title":"Initial clinical experience with (90)Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.04.008_bib0064","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:41:33Z","timestamp":1757544093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0001299822000393"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.04.008","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Role for PET\/CT in Response Assessment of Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}